Literature DB >> 30207225

Effect of Dapagliflozin on Intestinal Flora in MafA-deficient Mice.

Luyao Li1, Shiyao Xu2, Tingting Guo3, Shouliang Gong4, Chuan Zhang1.   

Abstract

OBJECTIVE: To investigate the effect of dapagliflozin on intestinal microflora in MafA-deficient mice using an animal model of diabetes.
METHODS: Male MafA-deficient mice were administered dapagliflozin (1.0 mg/kg/d) intragastrically for 6 weeks. Mouse body weights and fasting blood glucose levels were measured, and intestinal short-chain fatty acids were measured by gas chromatography. A series of methods was used to analyse the number of primary harmful bacteria in the faeces, and high-throughput sequencing was used to sequence the changes in intestinal flora.
RESULTS: The weight of the mice decreased after dapagliflozin gavage, and fasting blood glucose was significantly lower than that in the control group (P < 0.001). Acetic acid and butyric acid contents in the intestinal tracts of the mice increased, and the growth of harmful microorganisms, such as Clostridium perfringens, enterococci, Enterobacteriaceae, and intestinal enterococci, was inhibited. Blautia is a species found in the experimental group and was significantly different from the control and blank groups as determined by the LDA score from highthroughput sequencing.
CONCLUSION: Dapagliflozin can reduce fasting blood glucose, decrease body weight, increase short-chain fatty acid content, regulate the intestinal microecological balance of the body and promote blood glucose and energy homeostasis. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Dapagliflozin; Probiotics; Type 2 diabetes mellitus; blood glucose; energy homeostasis; intestinal microflora.

Mesh:

Substances:

Year:  2018        PMID: 30207225     DOI: 10.2174/1381612824666180912143434

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  5 in total

Review 1.  Gut Microbiota in Bone Health and Diabetes.

Authors:  Julie Kristine Knudsen; Peter Leutscher; Suzette Sørensen
Journal:  Curr Osteoporos Rep       Date:  2021-02-01       Impact factor: 5.096

Review 2.  AMP-Activated Protein Kinase and Host Defense against Infection.

Authors:  Prashanta Silwal; Jin Kyung Kim; Jae-Min Yuk; Eun-Kyeong Jo
Journal:  Int J Mol Sci       Date:  2018-11-06       Impact factor: 5.923

3.  Effects of Non-insulin Anti-hyperglycemic Agents on Gut Microbiota: A Systematic Review on Human and Animal Studies.

Authors:  Thao T B Cao; Kun-Chang Wu; Jye-Lin Hsu; Chih-Shiang Chang; Chiahung Chou; Chen-Yuan Lin; Yu-Min Liao; Pei-Chun Lin; Liang-Yo Yang; Hsiang-Wen Lin
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-23       Impact factor: 5.555

4.  Gut Microbiota Changes by an SGLT2 Inhibitor, Luseogliflozin, Alters Metabolites Compared with Those in a Low Carbohydrate Diet in db/db Mice.

Authors:  Shinnosuke Hata; Takuro Okamura; Ayaka Kobayashi; Ryo Bamba; Tomoki Miyoshi; Hanako Nakajima; Nobuko Kitagawa; Yoshitaka Hashimoto; Saori Majima; Takafumi Senmaru; Hiroshi Okada; Emi Ushigome; Naoko Nakanishi; Hiroshi Takakuwa; Ryoichi Sasano; Masahide Hamaguchi; Michiaki Fukui
Journal:  Nutrients       Date:  2022-08-27       Impact factor: 6.706

Review 5.  Effects of Oral Glucose-Lowering Agents on Gut Microbiota and Microbial Metabolites.

Authors:  Dongmei Wang; Jieying Liu; Liyuan Zhou; Qian Zhang; Ming Li; Xinhua Xiao
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-13       Impact factor: 6.055

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.